Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Fastbase Solutions
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Summary== Fastbase Solutions goal is to develop its microscopy platform, QF-Pro®, into an easy-to-use marketable healthcare product, that contributes to enhance immune-oncology treatments of cancer patients. Fastbase was founded by leading scientists from Cancer Research UK. After promising trial results,they now require funding to launch QF-Pro® commercially. * Awarded 'best predictive test for immune oncology' by industry experts and big Pharma * Immune oncology is a fast-growing cancer market (16.5% CAGR) * QF-Pro® technology is patented in all major international markets * We estimate that QF-Pro® could save between €25-€42k/patient in treatment costs (USA & EU) ==Idea== <vimeo>690851980</vimeo> We founded Fastbase with the goal of improving the lives of cancer patients. As cancer deaths exceed 10m people per year in 2020, we are developing a solution to target one of the root causes of cancer deaths: delivering proper diagnostics. Therefore, we have developed QF-Pro®, a molecular imaging technology that can map & quantify protein interactions & post-translational modifications in biopsies. These are important biological events. According to our research, their quantification by QF-Pro® can stratify patients for correct treatments, predict patient responses and survival. Our research indicates that no other product is currently offering a higher molecular resolution. Traction: * Cooperating with renowned laboratories worldwide * Demonstrated value in predicting patient response to immune-therapies & can predict patient survival in lung & skin cancer (published in Cancer Research) * QF-Pro® technology is protected by patents & licenses in the main markets * Won two international awards:the EU seal of excellence & MATWIN award in 2020. We require funding to begin our next phase: fully productising QF-Pro® & translating it to research & clinical laboratories worldwide. We believe it could improve patient outcomes of immune-oncology therapies. Our own research suggests we could expand into other diseases. The Immuno-oncology market is expected to grow at 16.5% CAGR to $37bn by 2028. ==Team== We at FASTBASE have assembled a diverse team with an assorted range of talents & backgrounds: '''Prof Peter J Parker: Founder & Chairman of Scientific Advisory Board''' FASTBASE Solutions was founded by Prof Peter J Parker, a decorated scientist who is a member of the Royal Society, a Morton prize winner & recently retired from King´s College and the Francis Crick Institute, London, where he headed the Protein Phosphorylation Laboratory. '''Mr. Fernando Aguirre (MSc): CEO''' Fernando has significant experience in company launches, he is the founder of 8 other companies & has held roles in companies such as Ericsson, the European Commission & Hasten Ventures. '''Dr. Veronique Calleja: CSO''' Veronique has a strong background in cell signalling, biophysics & microscopy. With a long career in science & work undertaken in the laboratory of Prof Parker, she is perfectly placed to evolve our science & applications into the marketplace. '''Dr. Juan Gumuzio: Operations Manager''' Juan is an experienced operations manager who has worked in biotech operations & streamlining efficiency whilst expanding product utility. '''Dr. James Miles (MPharmacol): Product Manager''' James has worked with QF-Pro® for many years and has completed his doctoral studies with us. With a background in bio-imaging, molecular biology and biomedicine, he is perfectly placed to help evolve our technology into a market ready product. [[Category:Thesis]] [[Category:Equities]] __INDEX__
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)